[氨磺必利的初步经验，一种在德国新型的非典型抗精神病药物用于治疗患有精神疾病的青少年]
[Initial experiences with amisulpride, an in Germany novel, atypical neuroleptic drug in treatment of adolescents with psychiatric disorders].
作者信息
Göpel C, Marcus A
机构信息
Krankenanstalt Mutterhaus der Borromäerinnen, Abteilung für Kinder- und Jugendpsychiatrie, Trier.
出版信息
Z Kinder Jugendpsychiatr Psychother. 2001 Aug;29(3):230-8. doi: 10.1024//1422-4917.29.3.230.
OBJECTIVES
In addition to conventional antipsychotic drugs, during the past decade an increasing number of atypical neuroleptics has been introduced in the treatment of juvenile schizophrenic and schizoaffective disorders. In 1999 Germany legalized the benzamide amisulpride for the treatment of acute and chronic schizophrenic symptoms. Preliminary treatment results are reported here.
METHODS
Ten adolescent cases are presented with regard to the efficacy, side effects and dosage of amisulpride.
RESULTS
Preliminary results on the use of amisulpride are promising. The rate of side effects is tolerable.
CONCLUSIONS
Amisulprise seems to constitute a useful alternative in the treatment of juvenile schizophrenia for those who suffer from intolerable side effects of classical or atypical neuroleptics. Controlled studies are warranted to further clarify its efficacy and safety in the treatment of adolescents.
目的
在过去十年中，除了传统抗精神病药物外，越来越多的非典型抗精神病药被用于治疗青少年精神分裂症和分裂情感性障碍。1999年，德国将苯甲酰胺类药物氨磺必利用于治疗急性和慢性精神分裂症症状合法化。本文报告了初步治疗结果。
方法
介绍了10例青少年患者使用氨磺必利的疗效、副作用及剂量情况。
结果
氨磺必利的初步使用结果令人鼓舞。副作用发生率可耐受。
结论
对于那些因使用经典或非典型抗精神病药出现难以耐受副作用的青少年精神分裂症患者，氨磺必利似乎是一种有效的替代药物。有必要进行对照研究以进一步明确其在青少年治疗中的疗效和安全性。
Zotero 插件